Bevacizumab in Wet AMD treatment: A tribute to the thirteen years of experience from the beginning of the anti‑VEGF era in Romania
- Horia T. Stanca
- Simona Stanca
- Bogdana Tabacaru
- Madalina Boruga
- Florian Balta
Affiliations: Department of Ophthalmology, ‘Carol Davila’ University of Medicine and Pharmacy, 050474 Bucharest, Romania, Department of Pediatrics, ‘Carol Davila’ University of Medicine and Pharmacy, 050474 Bucharest, Romania, Department of Pharmacy, ‘Victor Babes’ University of Medicine and Pharmacy, 300041 Timisoara, Romania
- Published online on: August 6, 2019 https://doi.org/10.3892/etm.2019.7858
Copyright: © Stanca
et al. This is an open access article distributed under the
terms of Creative
Commons Attribution License.
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
This study aimed to identify and describe anatomical and functional changes on short (1‑3 months) and medium (6‑12 months) term after intravitreal injections of bevacizumab (Avastin, Genentech) in patients with choroidal neovascularization (CNV) in the context of exudative form of age‑related macular degeneration (AMD). We performed a retrospective, analytical, interventional study, based on a series of cases with exudative form of AMD, which also comprised a prospective component related to the inclusion and treatment of the patients with a very new interventional method for that time (2006) and the follow‑up of the effects of intravitreal injection of bevacizumab (1.25 mg) therapy in three monthly doses for short (1‑3 months) and medium (6‑18 months) periods of time. The follow‑up of these patients was made by determining visual acuity (VA) as best corrected visual acuity (BCVA) at baseline and at every visit, slit lamp examination with contact or noncontact lenses each time, and optical coherence tomography and/or angiofluorography, applied only for certain patients, at various times of the study. In total, 376 intravitreal injections were administered to 117 eyes of 96 patients. The VA improved in the assessment of 3 months in 77 eyes (66%), either subjective (by the patient) or objectively quantified (by the physician). In 40 eyes (34%), there was no change in VA. In patients for whom optical coherence tomography could be performed, a significant reduction of the macula's thickness was found. The use of bevacizumab in subretinal neovascular membrane treatment is effective and safe on short and medium term, with the improvement of BCVA and reduction of macular edema in a significant number of cases.